DCIS (ductal carcinoma in situ) is a non-invasive breast cancer.
Many issues about how best to treat DCIS are under study, including:
After discussing the benefits and risks with your health care provider, we encourage you to consider joining a clinical trial.
BreastCancerTrials.org in collaboration with Susan G. Komen® offers a custom matching service to help you find a clinical trial that fits your health needs.
If you or a loved one needs information or resources about clinical trials, call our Clinical Trial Information Helpline at 1-877 GO KOMEN (1-877- 465- 6636) or email at firstname.lastname@example.org.
Learn more about clinical trials.
Radiation therapy after lumpectomy for DCIS decreases the risk [2-9]:
Overall survival is the same for women with DCIS who have lumpectomy with or without radiation therapy [2,3-4].
Since radiation therapy after lumpectomy for DCIS doesn’t improve survival, there are questions about the need for all women to get radiation therapy after lumpectomy for DCIS. Researchers are studying which women might be able to avoid radiation therapy after lumpectomy for DCIS.
At this time, some women with smaller, lower-grade DCIS and clean surgical margins may be able to have lumpectomy without radiation therapy [2,10].
For a summary of research studies on lumpectomy plus radiation therapy as a treatment for DCIS, visit the Breast Cancer Research Studies section.
Oncotype DX® is a test that helps predict the chance of metastasis (when cancer spreads to other organs) for some invasive breast cancers. It tests a sample of the tumor (removed during a biopsy or surgery) for a group of 21 genes.
The Oncotype DX test for invasive breast cancer has been modified to help predict the chance DCIS will return as DCIS or invasive breast cancer .
This might help identify which cases of DCIS would benefit most from radiation therapy after lumpectomy (and which women might be treated with lumpectomy alone) .
The Oncotype DX test for DCIS needs further study and isn’t part of standard practice at this time.
Learn more about Oncotype DX and treatment for invasive breast cancer.
Our commitment to research
At Susan G. Komen®, we are committed to saving lives by meeting the most critical needs in our communities and investing in breakthrough research to prevent and cure breast cancer. Our Research Program is an essential driving force for achieving this mission. Since our inception in 1982, Komen has provided funding to support research grants that have greatly expanded our knowledge of breast cancer and helped us understand that breast cancer is not just a single disease but many diseases, unique to each individual. Going forward, our commitment to research will contribute significantly to our ability to achieve our Bold Goal of reducing the current number of breast cancer deaths in the U.S. by 50 percent by 2026.
To date, Komen has provided more than $956M to researchers in 47 states, the District of Columbia and 21 countries to support research that has resulted in a better understanding of breast cancer; earlier detection; personalized, less invasive treatments for what was once a “one-treatment-fits-all” disease; and improvements in both quality of life and survival rates.
Learn more about our continuing investment in research and the exciting research that we are funding, because nothing would make us happier than ending breast cancer forever.
*Please note, the information provided within Komen Perspectives articles is only current as of the date of posting. Therefore, some information may be out of date at this time.
Interactive Treatment Navigation Tool
Breast Cancer Clinical Trial Information Helpline
1-877 GO KOMEN(1-877-465-6636)
What gives you strength during treatment?